Replies to post #4683 on Ariad Pharmaceuticals Inc fka ARIA

[yosarian_2]

One might think that the market would be rational, but it rarely is. Ponatinab is worth $11/share.
Rida is, until multiple indications come on board, worth $3/share. IMO buyout is $14/share.
Skal, Yo.

[Paulieme]

Page 1 of Clinical Trials for ridaforolimus, 28 Total Matches
http://clinicaltrialsfeeds.org/clinical-trials/results/term=ridaforolimus?pg=1